Compare FSTR & YDES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSTR | YDES |
|---|---|---|
| Founded | 1902 | 2013 |
| Country | United States | Taiwan |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 442.3M | 476.8M |
| IPO Year | 1995 | 2024 |
| Metric | FSTR | YDES |
|---|---|---|
| Price | $35.75 | $5.85 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 40.1K | ★ 380.9K |
| Earning Date | 11-02-2026 | 08-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.44 | N/A |
| Revenue | ★ $540,009,000.00 | N/A |
| Revenue This Year | $4.14 | N/A |
| Revenue Next Year | $2.54 | N/A |
| P/E Ratio | $80.20 | ★ N/A |
| Revenue Growth | ★ 1.74 | N/A |
| 52 Week Low | $24.30 | $1.70 |
| 52 Week High | $45.81 | $18.57 |
| Indicator | FSTR | YDES |
|---|---|---|
| Relative Strength Index (RSI) | 42.92 | 51.40 |
| Support Level | $27.44 | $4.97 |
| Resistance Level | $38.92 | $8.89 |
| Average True Range (ATR) | 0.89 | 1.01 |
| MACD | 0.03 | -0.18 |
| Stochastic Oscillator | 38.48 | 20.43 |
L.B. Foster Co is a technology solutions provider of products and services for the rail and infrastructure markets. The company has two reporting segments: Rail, Technologies, and Services (Rail); and Infrastructure Solutions (Infrastructure). Maximum revenue is generated from the Rail segment, which is comprised of several manufacturing and distribution businesses that provide products and services for freight and passenger railroads and industrial companies throughout the world. The Infrastructure segment offers engineered precast concrete solutions, as well as fabricated bridge, protective pipe coating, and pipe threading offerings across North America. Geographically, the company generates maximum revenue from the United States, followed by Canada, the UK, and other markets.
YD Bio Ltd is a biotechnology company focused on regulated diagnostics, life science clinical services and healthcare product commercialization. Its operations include DNA methylation-based oncology testing programs in the United States under an LDT framework with CLIA-certified and CAP-accredited laboratory partners. The Company also provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination and compliance-focused support for clinical development programs. It maintains ocular health product commercialization operations in the United States and consumer healthcare distribution activities in Asia. The Company operates in the United States and Taiwan, with Taiwan generating maximum revenue.